DAIICHI SANKYO, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

Completed

Conditions: Giant Cell Tumors

First Posted Date: 2016-10-28

Last Posted Date: 2023-10-31

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 183

Registration Number: NCT02948088

Locations: 🇩🇪
Westdeutsches Tumorzentrum, Essen, Germany
🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain
🇫🇷
CHU Nantes, Nantes, France

and more 12 locations

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban-based Regimen
Drug: VKA-based Regimen

First Posted Date: 2016-10-25

Last Posted Date: 2022-03-24

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1426

Registration Number: NCT02943785

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
University of Arizona Sarver Heart Center, Tucson, Arizona, United States
🇺🇸
Arkansas Site Management Services, Little Rock, Arkansas, United States

and more 227 locations

Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban

First Posted Date: 2016-10-25

Last Posted Date: 2022-06-01

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 13980

Registration Number: NCT02944019

Locations: 🇦🇹
Wilhelminenspital der Stadt Wien,Kardiologie,Wien, Wien, Austria
🇧🇪
Clinique St-Jean, Cardiology, Bruxelles, Bruxelles, Belgium
🇦🇹
Universitaetsklinik Graz, Onkologie, Graz, Graz, Austria

and more 720 locations

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Phase 1

Completed

Conditions: Pulmonary Embolism
Thrombotic Disease

Interventions: Drug: DS-1040b
Drug: Placebo
Drug: Enoxaparin

First Posted Date: 2016-10-04

Last Posted Date: 2023-04-19

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 134

Registration Number: NCT02923115

Locations: 🇳🇱
Albert Schweitzer Hospital, Dordrecht, Netherlands
🇺🇸
University of California, San Diego (UCSD) Medical Center, San Diego, California, United States
🇺🇸
Duke University Medical Center (DUMC), Durham, North Carolina, United States

and more 43 locations

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Phase 3

Completed

Conditions: Venous Thromboembolism (VTE)
Deep Vein Thrombosis (DVT)
Pulmonary Embolism

Interventions: Drug: Standard of Care
Drug: Edoxaban

First Posted Date: 2016-06-14

Last Posted Date: 2023-03-06

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 290

Registration Number: NCT02798471

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇭🇷
Clinical Hospital Centre Rijeka, Rijeka, Croatia

and more 137 locations

A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: DS-8500a

First Posted Date: 2016-06-06

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 12

Registration Number: NCT02790684

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: DS-8500a
Drug: Itraconazole

First Posted Date: 2016-06-06

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 26

Registration Number: NCT02790671

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

An Open Study Assessing the Safety and Tolerability of U3-1784

Phase 1

Terminated

Conditions: Advanced Solid Tumors
Hepatocellular Cancer (HCC)

Interventions: Drug: U3-1784

First Posted Date: 2016-02-24

Last Posted Date: 2018-05-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 10

Registration Number: NCT02690350

Locations: 🇬🇧
The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
Guy's Hospital, London, United Kingdom

Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 2

Withdrawn

Conditions: Neuropathic Pain
Diabetes

Interventions: Drug: DS-1971a
Drug: placebo
Drug: pregabalin

First Posted Date: 2016-02-04

Last Posted Date: 2016-07-27

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT02673866

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia
Leukemia

Interventions: Drug: Chemotherapy
Drug: Placebo
Drug: Quizartinib

First Posted Date: 2016-01-29

Last Posted Date: 2024-08-06

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 539

Registration Number: NCT02668653

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
University of Florida (UF) Health Shands Hospital, Gainesville, Florida, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

and more 240 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy